AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03258294
Drug: Melatonin(Circadin®)
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04272944
Drug: 10 mg/kg Q2W
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg MSB2311 every two weeks
Trial: NCT04272944
Drug: 20 mg/kg Q3W
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg MSB2311 every three weeks.
Trial: NCT00602459
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00079001
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT00079001
Drug: androgen deprivation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients concurrently enrolled on the Phase III study of intermittent androgen deprivation in patients with stage D2 prostate cancer will receive androgen deprivation therapy per SWOG-9346. All other patients will receive androgen deprivation therapy at a standard dose and schedule throughout the study.
Trial: NCT04301869
Drug: Antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral versus intravenous therapy
Trial: NCT00815542
Drug: prostaglandins E2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prostaglandins E2 - Intravaginal Propess for 24 hours
Trial: NCT01040637
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ascending doses
Trial: NCT04463251
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline (0.9% Sodium Chloride solution for Injection), 2 mL in the 4-mL transparent glass vial
Trial: NCT02173665
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02700373
Drug: PDC-APB
RxNorm normalized name: chlorpheniramine maleate / dihydrocodeine bitartrate / phenylephrine hydrochloride Oral Solution [Despec-PDC]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01868022
Drug: GSK3052230
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A clear to opalescent, colorless to pale yellow solution for IV infusion once weekly (Day 1, Day 8, Day 15) in each 21-day cycle with unit dose strengths/dose level of 5, 10, 15, and 20 mg/kg supplied in a sterile 25 mL glass vial.
Trial: NCT03640390
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group will receive normal saline infusion
Trial: NCT04397497
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching volume of diluent
Trial: NCT03318497
Drug: 3'-deoxy-3'-[F-18] fluorothymidine: [F-18]FLT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV The experimental 18F-FLT-PET/CT is required to be completed before initiation of chemotherapy. Labs and correlative radiology, as directed per clinical care, are required within 30 days prior to 18F-FLT-PET/CT; and 18F-FDG-PET/CT is required within 30 days before the 18F-FLT-PET/CT. Follow-up will comprise 24 months of standard practice treatment and follow up.
Trial: NCT03625466
Drug: LUM/IVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC tablets or granules for oral administration.
Trial: NCT03625466
Drug: LUM/IVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC granules for oral administration.
Trial: NCT01575834
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by subcutaneous injection once a month (QM)
Trial: NCT01927315
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Placebo tablets once daily
Trial: NCT02846181
Drug: [14C]-SK-1405
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02346357
Drug: Placebo Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00690677
Drug: LBH589
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LBH589 will be administered orally at a dose of 30mg (1 - 20mg capsule and 2 - 5g capsules) on Monday, Wednesday and Friday of each week (three times a week). Patients may continue treatment with oral LBH589 until they experience unacceptable toxicity that precludes further treatment, disease progression, and/or at the discretion of the investigator.~The LBH589 capsules should be swallowed by mouth with a glass of water in the morning. The recommended way to take LBH589 is after not eating for at least 2 hours. You should also not eat for another 2 hours after taking your LBH589 capsules. The daily dose of LBH589 should be taken at approximately the same time each day. You should avoid eating grapefruit, seville oranges, or drinking grapefruit or seville orange juice during the study.
Trial: NCT03839862
Drug: TNF-inhibition
RxNorm normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initiation of immunosuppression with any TNF-inhibitor, e.g. infliximab, etanercept or adalimumab
Trial: NCT01566539
Drug: Intranasal Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo sprays that are pH adjusted to comparable levels of the drugs given. Five puffs per nostril; ten puffs total.
Trial: NCT03259425
Drug: HF10
RxNorm normalized name: Hydrofluoric Acid 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 107th TCID50/mL, intratumoral injection to a single or multiple eligible tumors for a total of 5 mL; on days 0, 7, 14, 21, 28, 42, 56, 70, 84 for a total of 9 injections. All eligible tumors except one will be treated with HF10 up to the maximum volume allowed. The untreated tumor will be used as an untreated control lesion.
Trial: NCT02049905
Drug: Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02728505
Drug: SinuSurf irrigation twice daily
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02728505
Drug: NeilMed Sinus rinse irrigation twice daily
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00542009
Drug: CE-326,597 100 mg QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally, once daily with morning meal for duration of trial (84 days).
Trial: NCT00542009
Drug: CE-326,597 50 mg QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally, once daily with morning meal for duration of trial (84 days).
Trial: NCT00542009
Drug: CE-326,597 25 mg QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally, once daily with morning meal for duration of trial (84 days).
Trial: NCT00542009
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match CE-326,597 tablets to be administered orally, once daily with morning meal for duration of trial (84 days).
Trial: NCT00542009
Drug: CE-326,597 5mg QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally, once daily with morning meal for duration of trial (84 days).
Trial: NCT02892110
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg daily
Trial: NCT00267969
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form = solution for injection, route = SC administered at Weeks 0 and 4. At Weeks 12 and 16, placebo will be crossed over to receive ustekinumab 45 mg or 90 mg.
Trial: NCT01665157
Drug: low volume 1.5L PEG-ELS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low volume PEG-ELS
Trial: NCT02022280
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin pill
Trial: NCT03766867
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: concentrate for solution for infusion, 25 mL administered in 250 mL saline over 2 hours as single dose
Trial: NCT03766867
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration once daily
Trial: NCT02619864
Drug: AZD2014
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02390921
Drug: Fisiogen Ferro Forte
RxNorm normalized name: Ferro-Sequels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients will interrupt the endovenous treatment with iron and will receive liposomated iron 28mg/daily during 3 months.
Trial: NCT00893412
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03243032
Drug: Ibuprofen 600 mg
RxNorm normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 600mg given 30 minutes prior to beginning of surgery
Trial: NCT03243032
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Microcrystalline Cellulose NF (Avicel PH 105) - compounded at the University of Iowa College of Dentistry Pharmacy) given 30 minutes prior to beginning of surgery
Trial: NCT03243032
Drug: Local anesthetic Control
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine with 1:100,000 epinephrine as the local anesthetic for Group 2 - Control
Trial: NCT00650013
Drug: ProAmatine® Tablets 5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg, single dose fed
Trial: NCT01392924
Drug: SAR245408
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: tablet Route of administration: oral
Trial: NCT01152346
Drug: Vidaza®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg/m2 sc injection on Day 1 of either cycle 1 or cycle 2 per randomization assignment
Trial: NCT00005891
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02115581
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dose of 2 mg/kg/day in 2 or 3 divided doses and increased to the maximum dose of 10 mg/kg/day according to the patient's tolerance
Trial: NCT01839214
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00305084
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m² intravenous infusion over 15 minutes (starting 1 hour after the end of NGR-hTNF infusion)
Trial: NCT02555150
Drug: PRC-063
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral extended-release capsule
Trial: NCT02555150
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo capsule
Trial: NCT01873404
Drug: BG00010
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As specified in the treatment arm
Trial: NCT01873404
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As specified in the treatment arm
Trial: NCT01046903
Drug: Fragmin® (Dalteparin Sodium)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered per prescribing physician
Trial: NCT02329379
Drug: Levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00996151
Drug: Testosterone MD-Lotion
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose Testosterone MD-Lotion 2%
Trial: NCT02508077
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02508077
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT03046589
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: control to dose-escalation
Trial: NCT02523976
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02523976
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00613964
Drug: Carperitide heart failure therapy
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: carperitide(alpha-human atrial natriuretic peptide, 0.025-0.05μg/kg/min)
Trial: NCT00613964
Drug: Standard heart failure therapy
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loop diuretics, Aldosterone blockers, Beta blockers, ACE inhibitors, Angiotensin receptor blockers, Nitrates, digitalis
Trial: NCT00554918
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01240577
Drug: IPdR
RxNorm normalized name: DripDrop
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00554918
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02607774
Drug: AIN457
FDA approved: no
EMA approved: no
PMDA approved: no
Description: secukinumab administered at Weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24
Trial: NCT04161404
Drug: Brand name: Andrographis paniculata (Shine Hempedu Bumi) 1000mg capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Andrographis paniculata or hempedu bumi capsule is a traditional medicinal product registered under Ministry of Health Malaysia for general wealth being. It is traditionally used for anti-diabetic, anti-bacterial, anti-pyretic, anti-malarial, anti-inflammatory, antidiarrhoeal and other effects.
Trial: NCT00004237
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00004237
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02737254
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl 0,9 % nasal spray.
Trial: NCT05533008
Drug: CR845 0.5 mcg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV CR845 0.5 mcg/kg as a bolus injection
Trial: NCT00294372
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04232917
Drug: 2LPAPI®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment
Trial: NCT04232917
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03486080
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo control
Trial: NCT00708552
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comparator
Trial: NCT01223625
Drug: Rosuvastatin 5mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 5mg/day
Trial: NCT01223625
Drug: Rosuvastatin 40mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 40mg/day
Trial: NCT03867136
Drug: PZA sensitivity guided ultra-short all Oral Regimen
RxNorm normalized name: aspirin Oral Tablet [Anacin Aspirin Regimen]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrazinamide 1500 mg daily; Levofloxacin ≤50kg 500 mg daily, \>50kg 750mg daily; Linezolid: 600 mg daily; Cycloserine ≤50kg 500 mg daily, \>50kg 750mg daily; Clofazimine 100 mg daily; All treatment is taken daily;
Trial: NCT03867136
Drug: Standardized Shorter Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrazinamide 1500 mg daily;Levofloxacin 400 mg daily,; Prothionamide ≤50kg 500 mg daily, \>50kg 750mg daily; Ethambutol: ≤50kg 750 mg daily, \>50kg 1000mg daily; Clofazimine: 100 mg daily; Amikacin 600mg daily; High-dose isoniazid 600mg daily. All treatment is taken daily.
Trial: NCT05473949
Drug: Profofol for Sedation in Cholangiopancreatography for ASA III and ASA IV Patients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of 1% Propofol (Indution dose: 0.75mg/kg Maintenance dose: 6-7mg/kg/h) for Sedation in Cholangiopancreatography for ASA III and ASA IV Patients
Trial: NCT05473949
Drug: Ketofol for Sedation in Cholangiopancreatography for ASA III and ASA IV Patients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: use of Ketofol (1% Propofol + 5% Ketamine with a ratio 1/4) Indution dose: 0.75mg/kg Maintenance dose: 6-7mg/kg/h) for Sedation in Cholangiopancreatography for ASA III and ASA IV Patients
Trial: NCT00603902
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablet each morning and evening for a duration of 52 weeks.
Trial: NCT00981214
Drug: EUR-1008 (APT-1008)
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EUR-1008 (APT-1008) Microtabs contained in a capsule will be administered orally from Day 5 to Day 11 at an enzyme dose based on investigator's discretion, in dose stabilization period or the content of the capsule will be allowed to sprinkle on food, where necessary, followed by stabilized dose from Day 12 to Day 18 in treatment period, up to a maximum total dose of 10,000 lipase units per kilogram body weight per day (unit/kg/day).
Trial: NCT00675012
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: orally 825 mg/sqm 2qDx14
Trial: NCT03079141
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive 25 milligrams oral eplerenone once daily for a week, and - when no abnormalities during blood testing for potassium and renal clearance can be detected both before treatment and during the first week of treatment - will receive 50 milligrams oral eplerenone for another 11 weeks thereafter.~When patients are randomized to the eplerenone arm of this study, they will receive this treatment as a first cCSC treatment. Moreover, eplerenone treatment can be initiated in patients in whom SRF is still present on OCT at the Evaluation Visit at 3 months after PDT treatment.
Trial: NCT01125241
Drug: wuling capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally, three tablets each time,three times a day
Trial: NCT01125241
Drug: placebo of wuling capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally, three tablets each time and three times a day
Trial: NCT00003118
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003113
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide are given on days 22-31 of each cycle.
Trial: NCT00243295
Drug: rhBMP-2/CPM
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00707681
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4ml/vial
Trial: NCT00032149
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00032149
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02529449
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT02529449
Drug: ASP1941
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT03318978
Drug: [14C]-benzo[a]pyrene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral micro-dose range (25, 50, 100 and 250 ng)
Trial: NCT01224093
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: as prescribed
Trial: NCT02760823
Drug: Placebo (for Alpha Lipoic Acid)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline in syringe simulating Alpha Lipoic Acid 600mg
Trial: NCT00610155
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BID
Trial: NCT01488136
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose Ph capsules (Placebo)
Trial: NCT03882983
Drug: Antria Cell Preparation Process
RxNorm normalized name: Bos taurus red blood cell preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological/Vaccine: Stromal Vascular Fraction The SVF obtained from adipose tissue will be added to the graft~Other Names:~* Stromal Vascular Fraction~* Adiployx Biological/Vaccine:
Trial: NCT02337608
Drug: GLPG1205
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG1205 daily dosing in the morning for 12 weeks
Trial: NCT02337608
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo daily dosing in the morning daily for 12 weeks
Trial: NCT01254123
Drug: Placebo infusion.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On arrival to our cardiac care unit (CCU) and after informed consent patients will be randomized to Exenatide infusion or Placebo infusion. Patients in the placebo group will immediately be treated with placebo infusion.~Placebo preparation: 49ml saline and 1ml Human Serum Albumen (Cealb 200g/L, 10ml) to get a total of 50 ml will be placed in a 50cc syringe and placed in a pump system that is connected with a cannula in the patient's vein. The infusionrate will be 33,3 ml/hr for the first 30 minutes, followed by an infusion rate of 2,8 ml/hr for 72 hours. New 50cc syringes will be made every 8 hours.